Laboratory and clinical studies of temafloxacin

We performed laboratory and clinical evaluations of temafloxacin (TMFX), a new oral trifluorinated quinolone, with the following results. 1) Antimicrobial activity The minimum inhibitory concentrations (MICs) of TMFX for a total of 307 clinically isolated strains, were determined and compared with those of ofloxacin, tosufloxacin, ciprofloxacin, enoxacin and norfloxacin using the MIC-2000 system. TMFX had broad antimicrobial activities against all clinically isolated strains except methicillin-resistant Staphylococcus aureus (MRSA), Serratia marcescens and Pseudomonas aeruginosa. 2) Clinical efficacy TMFX, 150 mg × 2 (300 mg/day), was given to 2 patients with chronic bronchitis. Two patients with acute bronchitis and 4 with chronic bronchitis were treated with TMFX, 300 mg × 2 (600 mg/day). Clinical responses were good in all 8 patients. One strain of Haemophilus influenzae was eradicated while one strain of P. aeruginosa was not. No side effects were observed, but abnormal laboratory findings, including slight elevations in GOT GPT and eosinophils, were observed in 2 patients.